--Conference Call and Webcast today at 4:30pm ET-- HAMPTON, N.J. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2020 . The Company will host a conference call at 4:30 p.m.

HAMPTON, N.J. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will report second quarter 2020 financial results on Thursday, August 6, 2020 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m.

HAMPTON, N.J. , June 18, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the closing of its underwritten public offering of 15,384,614 shares (including 2,006,688 shares sold pursuant to the full exercise of the underwriters’ option

HAMPTON, N.J. , June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the pricing of its previously announced underwritten public offering. Celldex is offering 13,377,926 shares of its common stock, par value $0.001 per share, at a

HAMPTON, N.J. , June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.

--Data strongly support expanding development into mast cell driven diseases-- --Data presented in a late-breaking session at EAACI Annual Congress 2020-- HAMPTON, N.J. , June 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced results from the Company’s Phase 1

HAMPTON, N.J. , May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2020 . “Despite the ongoing challenges associated with the COVID-19 pandemic, Celldex continued to make considerable

HAMPTON, N.J. , May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that results from the Phase 1 study of CDX-0159 have been accepted as a late-breaking poster presentation with voice over at the European Academy of Allergy and Clinical Immunology (EAACI)

HAMPTON, N.J. , March 26, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2019 . “We are pleased that Celldex entered 2020 with significant momentum, following exciting data in late

Celldex also eligible to receive future milestone payments plus royalties HAMPTON, N.J. , March 03, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the Company will receive a $1.7 million payment related to an existing 2013 agreement with Rockefeller